

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/725,906	11/30/2000	Lisa McKerracher	06447-003-US-02	9776	
7590 06/26/2002			EXAMINER		
BROUILLETTE KOSIE  25th Floor 1100 Rene-Levesque Blvd. West Montreal, QC H3B 5C9			WEGERT, SANDRA L		
			ART UNIT	PAPER NUMBER	
CANADA			1647 DATE MAILED: 06/26/2002	10	

Please find below and/or attached an Office communication concerning this application or proceeding.

t	<u> </u>	Application No.		Applicant(s)					
Office Action Summary		09/725,906	١,	MCKERRACHER, LISA					
		Examiner	1	Art Unit					
		Sandra Wegert		1647					
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status		" 0000							
1)⊠	Responsive to communication(s) filed on <u>03 A</u>								
2a)☐	,	is action is non-fir							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Disposition	on of Claims		,						
4)🖂	Claim(s) <u>1-10</u> is/are pending in the application.	•							
4	4a) Of the above claim(s) is/are withdrawn from consideration.								
	) Claim(s) is/are allowed.								
	Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
•	Claim(s) <u>1-10</u> are subject to restriction and/or e	election requireme	ent.						
Application	·	_							
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.									
If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) ☐ All b) ☐ Some * c) ☐ None of:									
	1. Certified copies of the priority documents have been received.								
:	2. Certified copies of the priority documents have been received in Application No								
<ul> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
a) ☐ The translation of the foreign language provisional application has been received.  15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s)									
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲	Interview Summary (I Notice of Informal Pa Other:						

Application/Control Number: 09/725,906

Art Unit: 1647

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 2, 3, 5 and 6, drawn to a matrix and composition comprising collagen, for stimulating axon growth, classified in class 514, subclass 12+.
- II. Claims 1, 2, 4, 5 and 7, drawn to a matrix and composition comprising fibrin, for stimulating axon growth, classified in class 514, subclass 12+.
- III. Claims 8 and 9, drawn to a method of preparing a collagen composition for facilitating axon growth, classified in class 514, subclass 12+.
- IV. Claims 8 and 10, drawn to a method of preparing a fibrin composition for facilitating axon growth, classified in class 514, subclass 12+.

The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for Inventive Groups that are directed to different products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons: Groups I-II are independent and distinct, each from the other, because they contain products which possess characteristic differences in structure and function and each has an independent utility that is distinct for each invention which cannot be exchanged. The nucleic acid of group I can be used in gene therapy as well as in the production of the protein of interest.

Application/Control Number: 09/725,906

Art Unit: 1647

Collagen and fibrin are different in structure and matrices made from each have different functions.

Inventive Groups I and III are related as process of making and product made. The Inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product, or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05 (f)). In the instant case the matrix can be prepared by materially different processes, such as by chemical synthesis, or obtained from nature using various isolation and purification protocols.

Inventive Groups I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the method of making a fibrin matrix composition is unrelated to the collagen matrix.

Inventive Groups II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the method of making a collagen matrix composition is unrelated to the fibrin matrix.

Inventive Groups II and IV are related as process of making and product made. The Inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product, or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05 (f)). In the

Application/Control Number: 09/725,906 Page 4

Art Unit: 1647

instant case the matrix can be prepared by materially different processes, such as by chemical synthesis, or obtained from nature using various isolation and purification protocols.

Inventions III and IV are independent and distinct, each from the other, because the methods are practiced with materially different process steps for materially different purposes and each method requires a non-coextensive search because of different starting materials, process steps and goals.

Because these inventions are distinct for the reasons given above and the search required for each group is unique, as well as by their divergent subject matter and different search requirements, restriction for examination purposes as indicated is proper.

In response to this requirement, applicants must elect from Inventive Groups I through IV. Applicant is advised that in order for the reply to this requirement to be complete it must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the 1026currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(i).

Application/Control Number: 09/725,906

Art Unit: 1647

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (703) 308-9346. The examiner can normally be reached Monday - Friday from 9:30 AM to 6:00 PM (Eastern Time). If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached at (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

SLW

June 21, 2002

Elyabeth C. Kemme

ELIZABETH KEMMERER PRIMARY EXAMINER

Page 5